Diagnostic solutions provider Anbio has unveiled the Anbio AF-100S, an automated, compact, and affordable fluorescent Immunoassay (FIA) solution aimed at the landscape of clinical point-of-care (POC) diagnostics.

Anbio’s AF-100S FIA Solution is a handheld point-of-care immunodiagnostic solution that provides rapid, accurate, and reliable results for a wide range of analytes. 

The solution’s small size, long battery life, and interface make it ideal for use in a variety of settings, and its high sensitivity and specificity ensure that patients receive accurate results, the company says.

The AF-100S FIA Solution

The AF-100S FIA solution includes a compact FIA analyzer that measures at 195x100x70mm, and is aimed for use in private clinics, urgent care facilities, emergency rooms, and ambulances.

The analyzer can process up to 240 tests per hour, making it ideal for high-volume settings, and is powered by a lithium battery that provides up to 800 tests per charge, or 20 days of device off time.

The AF-100S FIA Solution also offers a wide range of assays for the detection of a variety of analytes, including hormones, enzymes, and infectious diseases.

Anbio’s AF-100S FIA solution uses fluorescently labeled antibodies or antigens to detect the presence of specific biomolecules in a patient’s sample. The sample is mixed with the labeled antibodies or antigens, and if the biomolecule is present, it will bind to the labeled molecules, forming a complex that emits a fluorescent signal, according to the company. The signal is then measured and compared to a known standard to determine the concentration of the biomolecule in the sample.

“The Anbio AF-100S is set to transform the field of clinical diagnostics, empowering healthcare providers with a cost-effective and comprehensive solution,” says Sa Jiang, chief marketing officer at Anbio. “Our FIA solution is small, yet powerful point-of-care immunodiagnostic solution that provides rapid, accurate, and reliable results for a wide range of analytes to provide faster diagnosis and better prognosis to patients.”

Featured image: Anbio